5-­LOXIN® Boswellia Serrata extract, standardized to 30% AKBA

 5-­LOXIN® boswellia serrata extract, standardized to 30% AKBA.

Edible Science is proud to offer the patented premier boswellia extract, a powerful agent in supporting healthy joint mobility.

5-LOXIN is a new, patent-pending joint health ingredient that is steeped in the historic roots of boswellia serrata extracts. The boswellia plant has been used for thousands of years in traditional Ayurvedic medicine in India, and recent studies have shown its benefits in promoting joint comfort, knee mobility and walking distance.*

An article published online on July 29, 2008 in the journal Arthritis Research & Therapy reported the finding of researchers at the University of California, Davis of significant  improvement in joint comfort and mobility in patients treated with the herb Boswellia serrata. Boswellia serrata, also known as frankincense, has been used for thousands of years in Indian Ayurvedic medicine, and has become popular in western countries.

For the current randomized, double-blinded trial, Siba Raychaudhuri and colleagues used a formulation called 5-Loxin®, which is an extract of Boswellia serrata enhanced with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA, the plant's most active ingredient). Seventy patients who had been qualified as good candidates for the study were divided to receive 100 or 250 milligrams 5-Loxin® per day, or a placebo for 90 days. Participants were evaluated after 1 week and at the end of each month until the study's conclusion, during which blood samples were collected and assessed for indicators of benefits. Matrix metalloproteinase-3, an enzyme involved in the degradation of joint tissues, was measured in knee synovial fluid at the beginning and end of the study.

As early as 7 days after beginning treatment with high dose 5-Loxin®, participants reported improvements in comfort and  functional ability. By the end of the study, both low and high dose-Loxin® were associated with  functional improvement, and synovial fluid matrix metalloproteinase-3 was reduced. No adverse treatment effects were noted.


• 5-LOXIN® is the most potent boswellic acid available, 
providing 30% AKBA
• Boswellic acids are natural, orally active, non-redox and non-competitive
5-lipoxygenase inhibitors.  There are six boswellic acids; however, AKBA
is the most active
• 5-LOXIN® provides a higher concentration of AKBA (standardized to
30%, while other Boswellic acid fractions contain only 2% - 3%)
• 5-LOXIN® is produced by the concentration of a naturally occurring
boswellic acid in a internationally patent-pending process 
• 5-LOXIN®  was shown to inhibit matrix metalloproteinase (MMP's), a class of enzyems that break down cartilage, collagen and connective tissues.
• 5-LOXIN® is safe-historic use and recent safety studies supports its use.

For centuries Traditional Ayurvedic Medicine has used boswellia serrata (frankincense), for its ability to support healthy connective tissue.1  The boswellic acids2, a group of triterpene acids isolated from the boswellic resin3, have been identified as the source of this activity.
 
These compounds work by inhibiting 5-lipoxygenase (5-LO), a key enzyme for the biosynthesis of leukotrienes and 5(S)-HETE from arachidonic acid.4-5 A detailed study on the structural effects of boswellic acids indicated, that out of all the natural boswellic acids, AKBA shows the most pronounced inhibitory activity.6
 
AKBA acts by a unique mechanism in which it binds to 5-LO in a calcium dependent, specific and reversible manner and acts as a non-redoxtype, non-competitive inhibitor.4,7 The properties of boswellic acids are not associated with generalized immune suppression.8

 5-LOXIN® provides up to 10x more AKBA than other boswellic acids9
 

Altmann, A., et al., Eur. J. Pharm. Sci. 11(1), S75, 2000. Altmann, A., et al., Arch. Pharm. Pharm. Med. Chem., 333(supp.2), 38, 2000.  2
Safayhi, H., et al., Planta Med., 63, 487-493, 1997. 
3 Pardhy, R. S., et al., Indian J. Chem., 16B, 176-178, 1978.
 4Sailer, E. R., et al., Eur.
J. Biochem., 256, 364-368, 1998. 
5 Safayhi, H., et al., Plant Med., 66, 110-113, 2000. 
6 Sailer, E. R., et al., British J. Pharmacol., 117, 615-
618, 1996. 
7 Safayhi, H. et al., J. Pharmaol. Exp. Ther., 261, 1143-1146, 1992. 
8 Sharma, M.L., et al., Phytotherapy Res., 10, 107-112,
1996. 
9 Laila Impex Research Centre, Comparison of 5-LOXIN to boswellia serrata extracts 2004.